Search

Author/Creator Denkert, C

1. 108OFactors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG database. (13th May 2019)

Authors:
Huober, J; Schneeweiss, A; Blohmer, J-U; Denkert, C; Hanusch, C; Jackisch, C; Nekljudova, V; Seither, F; Loibl, S; Untch, M
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 122TiPGeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (13th May 2019)

Authors:
Loibl, S; Jackisch, C; Rastogi, P; Seiler, S; Lucas, P C; Denkert, C; Costantino, J; Nekljudova, V; Wolmark, N; Geyer, C
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 168PValidation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC). (23rd October 2018)

Authors:
Fasching, P A; Laible, M; Weber, K E; Wirtz, R M; Denkert, C; Schlombs, K; Schmatloch, S; Camara, O; Lück, H J; Huober, J; Karn, T; van Mackelenbergh, M T; Marme, F; Müller, V; Schem, C; Stickeler, E; Sahin, U; Loibl, S; Untch, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 188PDImpact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (23rd October 2018)

Authors:
Untch, M; Jackisch, C; Schneeweiss, A; Schmatloch, S; Aktas, B; Denkert, C; Schem, C; Wiebringhaus, H; Kümmel, S; Rhiem, K; Warm, M; Fasching, P A; Just, M; Hanusch, C; Hackmann, J; Blohmer, J-U; Furlanetto, J; Nekljudova, V; von Minckwitz, G; Loibl, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 227PEvaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes. (23rd October 2018)

Authors:
Fasching, P A; Laible, M; Weber, K E; Wirtz, R M; Denkert, C; Schlombs, K; Schmatloch, S; Camara, O; Lück, H J; Huober, J; Karn, T; van Mackelenbergh, M T; Marme, F; Müller, V; Schem, C; Stickeler, E; Sahin, U; Loibl, S; Untch, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 243PGermline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. (23rd October 2018)

Authors:
Pohl, E; Schneeweiss, A; Hauke, J; Moebus, V; Furlanetto, J; Denkert, C; Fasching, P A; Hanusch, C; Tesch, H; Weber-Lassalle, N; Müller, V; Rhiem, K; Untch, M; Luebbe, K; Lederer, B; Jackisch, C; Nekljudova, V; Schmutzler, R K; Hahnen, E; Loibl, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 24TiPKEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer. (24th November 2019)

Authors:
Cardoso, F; Bardia, A; André, F; Cescon, D W; McArthur, H; Telli, M; Loi, S; Cortes, J; Schmid, P; Harbeck, N; Denkert, C; Jackisch, C; Jia, L; Hirshfield, K; Karantza, V
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 364TiPAnti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. (23rd October 2018)

Authors:
Decker, T; Denkert, C; Lübbe, K; Müller, V; Mundhenke, C; Furlanetto, J; Schmidt, M; Thill, M; Tierbach, V; Seither, F; Loibl, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 83TiPRESCUE: Reaching for evidence-based chemotherapy use in endocrine sensitive breast cancer - A prospective non-interventional study on risk assessment by the endopredict test and long-term patient outcome in early luminal breast cancer. (13th May 2019)

Authors:
Ettl, J; Blohmer, J-U; Denkert, C; Beier, L; Klein, E; Neuser, P; Keller, M; Untch, M; Wittenberg, M; Kiechle, M
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗